• +1-646-491-9876
    • +91-20-67278686

    Search

    Ocular Hypertension-Pipeline Review H2 2017

    Ocular Hypertension-Pipeline Review H2 2017

    • Report Code ID: RW00011022667
    • Category Life Sciences
    • No. of Pages 119
    • Publication Month Aug-17
    • Publisher Name Global Markets Direct
    Ocular Hypertension-Pipeline Review, H2 2017

    Summary

    Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Ocular Hypertension-Pipeline Review, H2 2017, provides an overview of the Ocular Hypertension (Ophthalmology) pipeline landscape.

    Ocular hypertension occurs when the pressure inside the eye (intraocular pressure) is higher than normal. If the aqueous humor does not flow through the trabecular meshwork properly, fluid pressure in the eye builds up, causing ocular hypertension. There are no symptoms with ocular hypertension. Risk factors include age, family history of glaucoma, lower systemic blood pressure, thinner central cornea and bleeding at the optic nerve head. Treatment includes eye drops to reduce intraocular pressure.

    Report Highlights

    Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Ocular Hypertension-Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Ocular Hypertension (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

    The Ocular Hypertension (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Ocular Hypertension and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I and Preclinical stages are 1, 1, 7, 14, 3 and 5 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

    Ocular Hypertension (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope

    -The pipeline guide provides a snapshot of the global therapeutic landscape of Ocular Hypertension (Ophthalmology).
    -The pipeline guide reviews pipeline therapeutics for Ocular Hypertension (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
    -The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    -The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
    -The pipeline guide reviews key companies involved in Ocular Hypertension (Ophthalmology) therapeutics and enlists all their major and minor projects.
    -The pipeline guide evaluates Ocular Hypertension (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
    -The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    -The pipeline guide reviews latest news related to pipeline therapeutics for Ocular Hypertension (Ophthalmology)

    Reasons to buy

    -Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
    -Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
    -Find and recognize significant and varied types of therapeutics under development for Ocular Hypertension (Ophthalmology).
    -Classify potential new clients or partners in the target demographic.
    -Develop tactical initiatives by understanding the focus areas of leading companies.
    -Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
    -Formulate corrective measures for pipeline projects by understanding Ocular Hypertension (Ophthalmology) pipeline depth and focus of Indication therapeutics.
    -Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    -Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
    Table of Contents
    Table of Contents 2
    List of Tables 3
    List of Figures 4
    Introduction 5
    Global Markets Direct Report Coverage 5
    Ocular Hypertension-Overview 6
    Ocular Hypertension-Therapeutics Development 7
    Pipeline Overview 7
    Pipeline by Companies 8
    Pipeline by Universities/Institutes 11
    Products under Development by Companies 12
    Products under Development by Universities/Institutes 14
    Ocular Hypertension-Therapeutics Assessment 15
    Assessment by Target 15
    Assessment by Mechanism of Action 17
    Assessment by Route of Administration 19
    Assessment by Molecule Type 21
    Ocular Hypertension-Companies Involved in Therapeutics Development 23
    Aerie Pharmaceuticals Inc 23
    Alcon Laboratories Inc 23
    Allergan Plc 24
    Bausch & Lomb Inc 24
    Can-Fite BioPharma Ltd 25
    D. Western Therapeutics Institute Inc 25
    F. Hoffmann-La Roche Ltd 26
    Ironwood Pharmaceuticals Inc 26
    Laboratoires Thea SA 27
    Laboratorios Sophia SA de CV 27
    Neurim Pharmaceuticals Ltd 28
    NicOx SA 28
    Ocular Therapeutix Inc 29
    Santen Pharmaceutical Co Ltd 30
    Senju Pharmaceutical Co Ltd 30
    Shire Plc 31
    Sun Pharma Advanced Research Company Ltd 31
    Sylentis SAU 32
    Ocular Hypertension-Drug Profiles 33
    (bimatoprost + timolol)-Drug Profile 33
    (latanoprost + netarsudil mesylate)-Drug Profile 34
    (latanoprost + timolol maleate)-Drug Profile 39
    bamosiran-Drug Profile 40
    bimatoprost ocular insert-Drug Profile 43
    bimatoprost SR-Drug Profile 45
    brimonidine tartrate-Drug Profile 47
    Gene Therapy to Target Matrix Metalloproteinase 1 for Steroid Induced Glaucoma and Ocular Hypertension-Drug Profile 48
    H-1129-Drug Profile 49
    IWP-953-Drug Profile 50
    latanoprost-Drug Profile 51
    latanoprost SR-Drug Profile 52
    latanoprost SR-Drug Profile 54
    latanoprost SR-Drug Profile 56
    latanoprostene bunod-Drug Profile 57
    MGV-354-Drug Profile 62
    NCX-1653-Drug Profile 63
    NCX-470-Drug Profile 64
    NCX-667-Drug Profile 66
    netarsudil mesylate-Drug Profile 67
    omidenepag isopropyl-Drug Profile 74
    piclidenoson-Drug Profile 76
    piromelatine-Drug Profile 86
    PRO-067-Drug Profile 88
    RO-5093151-Drug Profile 89
    sepetaprost-Drug Profile 90
    SHP-639-Drug Profile 91
    SJP-0135-Drug Profile 92
    SNJ-1656-Drug Profile 93
    travoprost ER-Drug Profile 95
    travoprost SR-Drug Profile 96
    travoprost XR-Drug Profile 98
    Ocular Hypertension-Dormant Projects 101
    Ocular Hypertension-Discontinued Products 103
    Ocular Hypertension-Product Development Milestones 104
    Featured News & Press Releases 104
    Appendix 115
    Methodology 115
    Coverage 115
    Secondary Research 115
    Primary Research 115
    Expert Panel Validation 115
    Contact Us 115
    Disclaimer 116

    List of Tables
    Number of Products under Development for Ocular Hypertension, H2 2017
    Number of Products under Development by Companies, H2 2017
    Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017
    Number of Products under Development by Universities/Institutes, H2 2017
    Products under Development by Companies, H2 2017
    Products under Development by Companies, H2 2017 (Contd..1), H2 2017
    Products under Development by Universities/Institutes, H2 2017
    Number of Products by Stage and Target, H2 2017
    Number of Products by Stage and Mechanism of Action, H2 2017
    Number of Products by Stage and Route of Administration, H2 2017
    Number of Products by Stage and Molecule Type, H2 2017
    Ocular Hypertension-Pipeline by Aerie Pharmaceuticals Inc, H2 2017
    Ocular Hypertension-Pipeline by Alcon Laboratories Inc, H2 2017
    Ocular Hypertension-Pipeline by Allergan Plc, H2 2017
    Ocular Hypertension-Pipeline by Bausch & Lomb Inc, H2 2017
    Ocular Hypertension-Pipeline by Can-Fite BioPharma Ltd, H2 2017
    Ocular Hypertension-Pipeline by D. Western Therapeutics Institute Inc, H2 2017
    Ocular Hypertension-Pipeline by F. Hoffmann-La Roche Ltd, H2 2017
    Ocular Hypertension-Pipeline by Ironwood Pharmaceuticals Inc, H2 2017
    Ocular Hypertension-Pipeline by Laboratoires Thea SA, H2 2017
    Ocular Hypertension-Pipeline by Laboratorios Sophia SA de CV, H2 2017
    Ocular Hypertension-Pipeline by Neurim Pharmaceuticals Ltd, H2 2017
    Ocular Hypertension-Pipeline by NicOx SA, H2 2017
    Ocular Hypertension-Pipeline by Ocular Therapeutix Inc, H2 2017
    Ocular Hypertension-Pipeline by Santen Pharmaceutical Co Ltd, H2 2017
    Ocular Hypertension-Pipeline by Senju Pharmaceutical Co Ltd, H2 2017
    Ocular Hypertension-Pipeline by Shire Plc, H2 2017
    Ocular Hypertension-Pipeline by Sun Pharma Advanced Research Company Ltd, H2 2017
    Ocular Hypertension-Pipeline by Sylentis SAU, H2 2017
    Ocular Hypertension-Dormant Projects, H2 2017
    Ocular Hypertension-Dormant Projects, H2 2017 (Contd..1), H2 2017
    Ocular Hypertension-Discontinued Products, H2 2017

    List of Figures
    Number of Products under Development for Ocular Hypertension, H2 2017
    Number of Products under Development by Companies, H2 2017
    Number of Products by Top 10 Targets, H2 2017
    Number of Products by Stage and Top 10 Targets, H2 2017
    Number of Products by Top 10 Mechanism of Actions, H2 2017
    Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
    Number of Products by Routes of Administration, H2 2017
    Number of Products by Stage and Routes of Administration, H2 2017
    Number of Products by Molecule Types, H2 2017
    Number of Products by Stage and Molecule Types, H2 2017
    Aerie Pharmaceuticals Inc
    Alcon Laboratories Inc
    Allergan Plc
    Bausch & Lomb Inc
    Can-Fite BioPharma Ltd
    D. Western Therapeutics Institute Inc
    F. Hoffmann-La Roche Ltd
    Ironwood Pharmaceuticals Inc
    Laboratoires Thea SA
    Laboratorios Sophia SA de CV
    Neurim Pharmaceuticals Ltd
    NicOx SA
    Ocular Therapeutix Inc
    Santen Pharmaceutical Co Ltd
    Senju Pharmaceutical Co Ltd
    Shire Plc
    Sun Pharma Advanced Research Company Ltd
    Sylentis SAU

    Request for Sample

    Report Url http://www.reportsweb.com//ocular-hypertension-pipeline-review-h2-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url http://www.reportsweb.com//ocular-hypertension-pipeline-review-h2-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url http://www.reportsweb.com//ocular-hypertension-pipeline-review-h2-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments